Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Efficacy and Safety of Adjuvant CDK4/6 Inhibitors in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study

To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Inclusion Criteria:

• Aged ≥18 and older
• Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
• HR+/HER2-
• ECOG 0-3
• Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors

Exclusion Criteria:

• During pregnancy or lactation
• Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption